Penile melanoma: a pathological report of two cases.
Melanoma
Mucosal Melanoma
PRAME
Staging
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
received:
24
07
2023
accepted:
20
10
2023
medline:
30
10
2023
pubmed:
29
10
2023
entrez:
29
10
2023
Statut:
epublish
Résumé
Penile melanoma (PM) is a rare tumor, accounting for less than 2% of all penile cancers. PM can occur on the surface of the glans, foreskin, and opening of the urethra. Furthermore, PM primarily affects older individuals and is not associated with sun exposure. Currently, there is no specific staging system for genitourinary tract melanomas, so these tumors are typically staged using the criteria for cutaneous melanoma. Limited data in the literature suggests that PM generally has a poor clinical prognosis. Here, we describe two cases of PM. The first case affected a 62-year-old male who presented with hematuria and a painful tumor in the distal urethra, leading to a suspicion of penile cancer. The second case involved a 68-year-old male who noticed a rapidly evolving dark spot on his foreskin. Histological analysis confirmed the presence of melanoma in both patients. The tumors showed a diffuse and strong PRAME-positivity and lacked BRAF mutation in both cases. Additionally, the second tumor harbored an activating CKIT mutation. An enhanced PD-L1 expression was observed in both tumors. We presented two rare forms of mucosal melanoma and highlighted the entities in the differential diagnosis. Based on our experience PRAME is a helpful marker for making the diagnosis of PM, and PD-L1 can predict the success of the immunotherapy. We also emphasize the need for an organ-specific staging system for PMs.
Sections du résumé
BACKGROUND
BACKGROUND
Penile melanoma (PM) is a rare tumor, accounting for less than 2% of all penile cancers. PM can occur on the surface of the glans, foreskin, and opening of the urethra. Furthermore, PM primarily affects older individuals and is not associated with sun exposure. Currently, there is no specific staging system for genitourinary tract melanomas, so these tumors are typically staged using the criteria for cutaneous melanoma. Limited data in the literature suggests that PM generally has a poor clinical prognosis.
CASE PRESENTATION
METHODS
Here, we describe two cases of PM. The first case affected a 62-year-old male who presented with hematuria and a painful tumor in the distal urethra, leading to a suspicion of penile cancer. The second case involved a 68-year-old male who noticed a rapidly evolving dark spot on his foreskin. Histological analysis confirmed the presence of melanoma in both patients. The tumors showed a diffuse and strong PRAME-positivity and lacked BRAF mutation in both cases. Additionally, the second tumor harbored an activating CKIT mutation. An enhanced PD-L1 expression was observed in both tumors.
CONCLUSIONS
CONCLUSIONS
We presented two rare forms of mucosal melanoma and highlighted the entities in the differential diagnosis. Based on our experience PRAME is a helpful marker for making the diagnosis of PM, and PD-L1 can predict the success of the immunotherapy. We also emphasize the need for an organ-specific staging system for PMs.
Identifiants
pubmed: 37898793
doi: 10.1186/s13000-023-01404-x
pii: 10.1186/s13000-023-01404-x
pmc: PMC10613369
doi:
Substances chimiques
B7-H1 Antigen
0
PRAME protein, human
0
Antigens, Neoplasm
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Informations de copyright
© 2023. The Author(s).
Références
Clin Oncol (R Coll Radiol). 1992 Mar;4(2):130-1
pubmed: 1372819
Arch Dermatol. 1978 Jan;114(1):67-9
pubmed: 619785
Melanoma Res. 2022 Feb 1;32(1):27-34
pubmed: 34840322
Melanoma Res. 2006 Jun;16(3):259-61
pubmed: 16718273
Cancer. 1953 Jan;6(1):1-45
pubmed: 13009650
Am J Surg Pathol. 2018 Nov;42(11):1456-1465
pubmed: 30045064
J Urol. 1974 Feb;111(2):198-200
pubmed: 4810764
World J Urol. 2009 Apr;27(2):169-77
pubmed: 18766352
Histopathology. 2018 Feb;72(3):472-480
pubmed: 28881040
Acta Derm Venereol. 2021 Apr 12;101(4):adv00426
pubmed: 33283249
J Urol. 2005 Jun;173(6):1958-65
pubmed: 15879790
Int J Surg Pathol. 2011 Oct;19(5):597-606
pubmed: 20075023
Am J Surg Pathol. 2023 May 1;47(5):599-610
pubmed: 36912431
Front Immunol. 2021 Jun 04;12:680407
pubmed: 34149718
Lab Invest. 2017 Sep;97(9):1063-1071
pubmed: 28737763
Histopathology. 2023 Jan;82(2):285-295
pubmed: 36200756
J Clin Diagn Res. 2016 Jul;10(7):XD01-XD02
pubmed: 27630937
Eur J Cancer. 2020 Aug;135:22-30
pubmed: 32531566
Urology. 2007 Jul;70(1):143-7
pubmed: 17656225
Urology. 2014 Jan;83(1):6-11
pubmed: 23978371
Hautarzt. 2005 Jun;56(6):540-9
pubmed: 15905972